Deletion of protein kinase C-ε attenuates mitochondrial dysfunction and ameliorates ischemic renal injury

Grazyna Nowak1, Diana Takacsova-Bakajsova2, Judit Megyesi3

  • 1Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas; and gnowak@uams.edu.

Insights

Deleting protein kinase C-epsilon (PKC-ε) protects kidney mitochondria from ischemia-induced dysfunction and preserves renal function. This highlights PKC-ε as a key factor in kidney injury after ischemia.

Area of Science:

  • Nephrology
  • Mitochondrial Biology
  • Biochemistry

Background:

  • Protein kinase C-epsilon (PKC-ε) activation is implicated in mitochondrial dysfunction in renal proximal tubule cells (RPTC).
  • The role of PKC-ε in overall kidney function following ischemic injury remains to be fully elucidated.

Purpose of the Study:

  • To investigate the impact of PKC-ε deletion on renal cortical mitochondrial function and kidney function after ischemia.
  • To determine if inhibiting PKC-ε can mitigate ischemia-reperfusion injury in the kidneys.

Main Methods:

  • Utilized wild-type (WT) and PKC-ε-deficient (KO) mouse models subjected to renal ischemia.
  • Assessed mitochondrial respiration (complex I and II coupling, respiratory control ratio), enzyme activities (complexes I, III, IV), oxidant production, and plasma creatinine levels.
  • Performed proteomics analysis and histological examination of kidney tissues; conducted in vitro studies using hypoxic RPTC.

Main Results:

  • PKC-ε deletion preserved mitochondrial respiration and enzyme activities in ischemic kidneys compared to WT.
  • PKC-ε deficiency reduced ischemia-induced oxidant production and attenuated increases in plasma creatinine.
  • Histological analysis showed reduced tubular necrosis and damage in KO mice; in vitro studies confirmed PKC-ε's detrimental role.

Conclusions:

  • PKC-ε activation is a critical mediator of mitochondrial dysfunction, specifically affecting respiratory chain complexes I and III, and oxidant production during renal ischemia.
  • Deletion of PKC-ε significantly protects against ischemia-induced kidney damage and functional decline.
  • Targeting PKC-ε represents a potential therapeutic strategy for preventing or treating acute kidney injury.